A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fib… (NCT03142191) | Clinical Trial Compass
TerminatedPhase 2
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Stopped: Business objectives have changed.
United States138 participantsStarted 2017-07-26
Plain-language summary
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subject is male or female ≥ 40 years of age
✓. Diagnosis of IPF is supported by HRCT and historical lung biopsy (surgical lung biopsy \[SLB\] or cryobiopsy) if available according to guidelines.
✓. No features supporting an alternative diagnosis on transbronchial biopsy, bronchoalveolar lavage (BAL), or SLB, if performed.
✓. Percent predicted forced vital capacity (% FVC) ≥ 45% and ≤ 95% at Screening
✓. Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 25% and ≤ 90% predicted at Screening.
✓. Able to walk ≥ 150 meters during the 6-minute walk test (6MWT) at Screening
✓. Females of childbearing potential (FCBP) must commit to true abstinence or agree to use two effective birth control methods.
✓. Male subjects must practice true abstinence or use a barrier method of contraception.
Exclusion criteria
✕
What they're measuring
1
Percentage Point Difference in % Predicted Forced Vital Capacity (FVC).
. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
✕. Subject with a QTcF \> 450 msec.
✕. Evidence of clinically relevant airways obstruction at Screening.
✕. Subjects using therapy targeted to treat IPF.
✕. History of latent or active TB, unless there is medical record documentation of successful completion of a standard course of treatment
✕. History of hepatitis B and/or hepatitis C, including those considered successfully treated/cured